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OPIOID OVERDOSES IN INDIANA:
A CLOSER LOOK AT OPIOID TYPE
Summary
 » The misuse of prescription and illicit opioids remains at epidemic proportions throughout the nation, 
costing the United States billions of dollars annually.  
 » Overdose deaths in both the U.S. and Indiana have seen a dramatic rise over the past ten years. Until 
recently, prescription opioids were responsible for the greatest number of overdose deaths across the 
country, but now have been surpassed by those from heroin and illicitly manufactured narcotics, primarily 
fentanyl. 
 » Persons at greatest risk for a fatal overdose include: 
 ○ those who use opioids jointly with alcohol or benzodiazepines, 
 ○ those who have chronic health conditions, 
 ○ those who have a history of nonfatal overdoses, and 
 ○ those who have recently been released from substance abuse treatment or incarceration. 
 » A number of approaches are available to help prevent fatal overdoses, including:
 ○Strengthening guidelines for the prescribing of opioids and enacting pain clinic laws to help 
prevent long-term use of these drugs and limit the risk of diversion; 
 ○Encouraging healthcare professionals who prescribe and/or dispense opioids to use 
prescription drug monitoring programs in order to monitor opioid use by their patients; 
 ○ Increasing the availability of medication-assisted treatment in order to help those addicted to 
opioids to stop using them; and 
 ○Enhancing availability of and access to naloxone to users of opioids, their families, and persons 
in the community.
INTRODUCTION
The United States’ ongoing opioid epidemic 
remains a serious public health threat for the 
nation. The most commonly abused opioids by 
U.S. citizens are prescription pain medication 
and heroin, although recently, the use of illegally 
manufactured fentanyl has risen significantly 
[1-3]. The opioid epidemic cost the nation $504 
billion in 2015 due to lost productivity, substance 
use treatment, healthcare, criminal justice, social 
service expenditures, and loss of life [4]. Loss of life 
due to overdose is the most tragic consequence 
of the opioid epidemic, a consequence that has 
been dramatically increasing in frequency for at 
least the last decade [1, 5]. The purpose of this 
brief report is to give a summary of the prevalence 
of opioid use, highlight the rates of fatal overdoses 
attributable to opioids, describe the risk factors 
for fatal overdoses, and suggest policies that 
could potentially help decrease the rate of such 
overdoses in Indiana.
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*Note: In 2014, the NSDUH revised its methodology for collection information on use of opioid 
analgesics, hence data are not available for 2014. Due to this change, data from 2015 and 2016 are 
not directly comparable to data from previous years.
THE OPIOID EPIDEMIC AND RATES OF 
OPIOID USE
The start of the opioid epidemic can be traced 
back to the late 1990s and the campaign by the 
American Pain Society (APS) to acknowledge pain 
as the fifth vital sign while simultaneously promot-
ing opioid analgesics as a safe form of treatment. 
The APS campaign led to a dramatic increase in 
both production and prescribing of opioid-based 
pain medications as well as the diversion of these 
drugs for nonmedical use. As a consequence, the 
nation experienced a steady rise in both medical 
and nonmedical opioid use and a concomitant rise 
in the number of individuals developing opioid use 
disorders and addiction. In an attempt to curb illicit 
use, pharmaceutical companies released abuse-de-
terrent formulations of their drugs while states 
established prescription monitoring programs and 
implemented stricter prescribing guidelines as 
methods for decreasing overall prescribing of these 
drugs [6, 7]. Consequently, many users of prescrip-
tion opioids transitioned to heroin use as a cheaper, 
more accessible, more powerful alternative, while 
new users of opioids often began their use with 
heroin rather than prescription pain medication 
[7-9]. More recently, the powerful synthetic opioid 
fentanyl, which is often illicitly produced, and its 
derivatives (e.g., carfentanil) have seen increased 
popularity as drugs of abuse either on their own or 
in combination with heroin [2, 3, 10].
Nationally, abuse of prescription opioids peaked 
in 2009, when the National Survey of Drug Use 
and Health (NSDUH) estimated that 5,257,000 US 
citizens ages 12 and older were using opioids. By 
2016, the number of current users had dropped by 
approximately 36% to 3,350,000. As prescription 
drug misuse declined, heroin use began to rise. 
The NSDUH reported that in 2016, there were 
475,000 current heroin users 12 years of age and 
Figure 1. Number of current (past-month) users of prescription opioids and
heroin in the United States*
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older, more than in 
any previous year. 
This represented a 
210% increase from 
2007 (see Figure 1). 
Although data on 
current use of heroin 
or opioid analgesics 
are not available for 
Indiana, the NSDUH 
estimated that in 
2016, approximately 
24,000 Hoosiers (or 
0.4%) ages 12 and 
older used heroin and 
270,000 (or 4.9%) 
misused opioid 
analgesics in the past 
year [11].
Evidence of the 
overall increase 
1Opiates/synthetics include the following drugs:  buprenorphine, codeine, hydrocodone, hydromorphone, meperidine, mor-
phine, opium, oxycodone, pentazocine, propoxyphene, tramadol, and any other drug with morphine-like effects
Figure 2. Percentage of treatment admissions with reported opioid misuse (TEDS 
2007-2015)
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in the use of opioids also comes from the 
Treatment Episode Data Set (TEDS) which collects 
information on individuals entering substance 
use treatment. Nationally, persons entering 
treatment who reported the use of any opioid (i.e., 
heroin, nonprescription methadone, or opiates/
synthetics1) increased from 23.4% of admissions 
in 2007 to 40.5% of admissions in 2015. Similarly, 
heroin was reported by 30.1% of admissions in 
2015, an 88% increase from 2007. Admissions 
who reported using other opiates/synthetics 
increased from 8.6% in 2007 peaking at 16.0% 
in 2011 and 2012 and having dropped slightly to 
14.0% in 2015. Indiana has experienced similar 
trends; however, the percentage of admissions to 
treatment in Indiana reporting prescription opioids 
has consistently been higher than that seen in the 
rest of the country (see Figure 2) [12].
PREVALENCE OF NON-FATAL AND FATAL 
OPIOID OVERDOSES
Nonfatal Overdoses
An individual can experience an overdose when 
she or he consumes a larger quantity or a stronger 
dose of an opioid than the body is capable of 
metabolizing. The symptoms of an opioid overdose 
typically include sleepiness, problems breathing, 
low blood pressure, spasms, and coma, among 
others. Without appropriate medical attention, 
overdoses can result not only in serious, long-
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term medical consequences, 
but also death [13]. Because 
many people who experience 
an overdose and subsequently 
survive never seek medical 
attention, the actual number of 
nonfatal overdoses occurring 
annually is not known. Data 
from the Healthcare Cost and 
Utilization Project (HCUP) show 
that rates of both emergency 
department (ED) and inpatient 
(IP) hospitalizations involving 
opioid-related injuries have 
climbed steadily, increasing 
from 2006 to 2015 by 243% and 
96% respectively [14], with the 
CDC reporting similar trends 
for 2016 through 2017 [15]. The 
Indiana State Department of 
Health (ISDH) indicates that the 
number of individuals admitted 
into Indiana’s emergency 
departments specifically for 
opioid overdoses rose from 1,460 
admissions in 2009 to 3,199 
admissions in 2016, a 119% 
increase (see Figures 3 and 4).
Fatal Overdoses
The most extreme outcome 
from an overdose is death, 
primarily as a result of the severe 
respiratory depression that 
can be triggered by ingesting 
high levels of opioids [16]. The 
number of drug overdose deaths 
across the country has gone 
up over the past decade to the 
point that overdoses are now 
responsible for more deaths 
annually than automobile 
Figure 3. Rates Per 100,000 Population of Admissions to Indiana Emer-
gency Departments (ED) and Inpatient (IP) Units for Opioid-related 
Injuries (AHRQ, 2006-2015)
Source: Healthcare Cost and Utilization Project
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
ED Admissions 59.6 75.4 91.9 98.5 116.9 125.9 133.4 138.6 152.3 204.3
IP Admissions 114.4 121.1 132.7 148.9 157.1 177.4 180.7 192.6 196.9 224.6
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Figure 4. Number of Admissions to Indiana Emergency Departments 
for Opioid Overdoses (ISDH, 2009-2016)
Source: Indiana State Department of Health
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accidents [1].  In 2016, a total 
of 63,602 U.S. citizens died 
from a drug-related overdose, 
representing a 77% increase 
in such deaths since 2007. 
Opioids are responsible for the 
majority of these deaths. In 2016, 
more than 42,000 deaths, or 
66% of drug overdose deaths 
nationally, were due to opioids. 
Deaths due to heroin, synthetic 
narcotics (e.g., fentanyl), and 
other opioids (i.e., prescription 
opioids excluding methadone 
or synthetically produced 
narcotics) have risen annually 
since 2007. Until recently, 
prescription-type opioids were 
responsible for the greatest 
number of overdose deaths; 
however, by 2015, heroin 
accounted for more deaths 
than any other opioid; by 2016, 
synthetic narcotics accounted 
for more deaths than either 
heroin or other opioids [17] (see 
Figure 5). 
Indiana has not been spared 
from the increase in overdose 
deaths. Comparably to what 
has occurred nationally, drug 
overdose deaths in Indiana have 
climbed annually from a low of 
781 deaths in 2007 to a high of 
1,526 deaths in 2016, a 95% 
increase. As is the case with the 
U.S., opioids are responsible 
for the majority of these deaths 
(54.5%). Prescription-type 
opioids were tied to more deaths 
than either heroin or synthetic 
opioids until 2013 when heroin 
Figure 5. Number of Overdose Deaths Attributable to Specific Opioids, 
U.S. 2007-2016
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became responsible for more deaths. This pattern 
held until 2016 when more fatal overdoses were 
tied to synthetic narcotics than to either heroin or 
prescription-type opioids [17] (see Figure 6).
Demographic Composition of Fatal Opioid 
Overdoses in Indiana
The demographic makeup of Hoosiers who have 
died from any type of opioid overdose has changed 
little over time. Since 2007, men have accounted 
for a greater percentage of opioid overdose 
deaths than women. Opioid overdose deaths have 
increased sharply among both genders; between 
2007 and 2016, the number of deaths rose 222% 
for men and 244% for women. Persons who have 
died from an opioid overdose were overwhelmingly 
white, accounting for over 90% of opioid overdose 
deaths during that 10-year period; though opioid 
overdose deaths increased for both White and 
Black Hoosiers. In terms of age, between 2007 
Figure 7. Number of Opioid Overdose Deaths in Indiana by Gender, 2007-2016
79
272
162
522
0
100
200
300
400
500
600
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Female Male
Figure 8. Number of Opioid Overdose Deaths in Indiana by Race, 2007-2016
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Figure 9. Number of Opioid Overdose Deaths in Indiana by Age Group,
2007-2016
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and 2016, the majority of opioid overdose deaths 
occurred among persons between the ages of 25 
to 54. Since 2010, individuals between the ages of 
25 to 34 have accounted for the largest percentage 
of opioid overdose deaths in the state (see Figures 
7-9). 
We compared the demographic composition of 
Hoosiers who died from overdosing on heroin, 
prescription opioids, or synthetic narcotics in 2016. 
Although men accounted for the majority of deaths 
in each drug category, women were more strongly 
represented in deaths associated with prescription 
opioids. Whites composed the majority of overdose 
deaths in all opioid categories; however, the 
percentage of Blacks who overdosed was highest 
within the synthetic narcotic group. Deaths among 
younger individuals, those between ages 15 and 34, 
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Heroin Other Opioids Synthetic Narcotics
N % Rate N % Rate N % Rate
Gender
Female 73 24.6 2.3 109 47.2 3.2 100 32.9 3.2
Male 224 75.4 6.9 122 52.8 3.8 204 67.1 6.6
Race
Black 26 8.8 3.9 16 6.9 UR 40 13.2 6.0
White 270 91.2 5.1 214 92.6 3.8 263 86.5 5.0
Missing/suppressed 1 0.3 - 1 0.4 - 1 0.3 -
Age
15-24 32 10.8 3.4 - - 29 9.5 3.1
25-34 113 38.0 13.1 63 27.3 7.3 107 35.2 12.4
35-44 63 21.2 7.7 43 18.6 5.3 77 25.3 9.4
45-54 58 19.5 6.7 66 28.6 7.6 54 17.8 6.2
55-64 27 9.0 3.1 55 23.8 5.1 32 10.5 3.7
Missing/suppressed 4 1.3 - 4 1.7 - 5 1.6 -
Note: The CDC defines other opioids as any natural or semisynthetic opioid (e.g., morphine) and synthetic narcotics 
as synthetic opioids other than methadone (e.g., fentanyl).
Table 1. Number, Percentage, and Rate per 100,000 population of Opioid Overdose Deaths in Indiana, by 
Opioid Type and Demographic Characteristics, 2016 
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were more prevalent among heroin and synthetic-
narcotic-related overdoses, but overdose deaths 
linked to prescription opioids were more frequent 
among Hoosiers ages 45 and older (see Table 1).
RISK FACTORS FOR FATAL OPIOID
OVERDOSES
General Risk Factors
The most significant risk factor for a fatal overdose, 
regardless of whether it was due to a prescription 
opioid or to an illicit opioid, is having a past history 
of nonfatal overdoses, with the risk rising in relation 
to the number of nonfatal overdoses [18-27].
A second risk factor for both fatal and nonfatal 
overdose is the concurrent use of opioids and 
benzodiazepines or other central nervous system 
depressants (e.g., alcohol or muscle relaxants), all 
of which can intensify the physiological effects of 
opioids [21, 23, 24, 26-35]. 
The risk of overdose is also increased among 
individuals who:
• use opioids and have chronic health condi-
tions, especially those associated with chronic, 
non-cancer pain; 
• are seropositive for hepatitis C (HCV) or HIV 
[19, 24, 29, 36]; 
• have a current or past history of substance use 
disorders, polysubstance use, or concurrent 
use or misuse of multiple opioids [20, 23, 26, 
31, 32, 35]; 
• have a history of mental health problems, es-
pecially problems related to depression and/or 
anxiety [20, 23, 24, 27, 29, 31, 32, 35-37]; or 
• have made a suicide attempt [23, 27].
Two groups who are at especially high risk for 
fatal and nonfatal overdoses are persons who are 
leaving incarceration or who have been discharged 
from an inpatient, abstinence-based detoxification 
facility. Persons in these situations are particularly 
vulnerable to overdose, especially within the first 
four weeks post-discharge, due to decreased 
physiological tolerance for opioids [21, 22, 34, 38, 
39].
Substance-Specific Risk Factors
Some risk factors for overdose vary according to 
the particular opioid used. Among individuals who 
use prescription opioids, overdose is more likely 
to occur in those who receive prescriptions with 
higher morphine milligram equivalents (MME); the 
risk for overdose increases in relation to the MME 
prescribed [23, 28, 30-32]. Persons who receive 
prescriptions for multiple types of opioids [24, 32], 
who receive opioids from a physician with liberal 
opioid prescribing practices [40], and who receive 
opioid prescriptions from multiple prescribers 
(engaging in doctor-shopping) or fill opioid 
prescriptions at multiple pharmacies (engaging 
in pharmacy-shopping) are also at greater risk 
for experiencing an overdose. Demographically, 
persons who suffer fatal overdoses due to 
prescription opioids are typically male, 50 years of 
age or older, and White.
For persons who use heroin or other opiates, 
overdose risk is particularly high among those 
who engage in injection use. Large quantities 
of a drug can be administered in this fashion, 
and the physiological effects of the drug occur 
almost immediately [18-21, 24, 37]. Other 
factors associated with fatal and nonfatal heroin 
overdoses are injecting drugs alone, having 
disrupted life circumstances (e.g., homelessness, 
unemployment), experiencing conflicts in 
one’s social network, and knowing someone or 
witnessing someone who has overdosed [20, 41]. 
Demographically, individuals who die from a heroin 
overdose are most often male, White, and between 
the ages of 25 to 34 [24, 27, 31, 41].
10
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For persons who use heroin or other 
opiates, overdose risk is particularly 
high among those who engage in 
injection use.
METHODS TO REDUCE FATAL OPIOID 
OVERDOSES
Reducing the prevalence of fatal opioid overdoses 
requires a multi-pronged approach to: 
(1) Prevent or reduce exposure to opioids
(2) Reduce the risk of overdose among those who 
may be abusing opioids, through identification 
and provision of treatment, and 
(3) Increase the chances of survival among those 
individuals who do experience an overdose.  
The following strategies can assist in meeting the 
above mentioned goals. 
Prescribing Guidelines
In 2016, the CDC released a set of prescribing 
guidelines to help medical providers understand 
the proper use of opioid medication [42]. When 
followed, the CDC’s prescribing guidelines can 
serve as an overdose prevention tool by reducing 
the number of individuals who are exposed to 
opioid medication and, over time, decreasing the 
number of individuals who could potentially be 
at risk for overdose. For persons who are already 
taking opioids, the prescribing guidelines can 
lessen their risk of overdose by encouraging 
providers to use the lowest dose of opioids possible 
for symptom relief, to use safer opioid formulations, 
to limit the number of pills prescribed, to refrain 
from prescribing opioids and benzodiazepines 
together, and to regularly monitor patients on 
opioid medication for signs of abuse and arrange 
treatment if necessary [42]. With proper oversight, 
prescribing guidelines can bring about positive 
changes in opioid prescribing behaviors [43-46]. In 
at least one state, the guidelines helped reduce fatal 
overdoses [47].
Opioid Prescribing Laws
Prescription drug overdoses are generally driven 
by a small number of medical providers who 
prescribe and/or dispense a high volume of opioids 
inappropriately or for nonmedical reasons (i.e., 
“pill mills”) [48]. Many states have enacted pain 
clinic laws as a way to control this type of improper 
prescribing. Implementation of such laws in Texas 
was associated with a decrease in the overall 
volume, strength, and monthly quantity of opioids 
dispensed [49] and in Florida with a significant drop 
in fatal opioid overdoses [50].
Prescription Drug Monitoring Programs
Prescription drug monitoring programs (PDMP) are 
another tool that can help reduce fatal overdoses. 
PDMPs are databases that collect information on 
dispensations of controlled substance medication, 
including opioids. The information gathered 
typically includes the name of the prescriber, 
details of the medication prescribed, the name, 
gender, and driver’s license number of the person 
who filled the prescription; and the name and 
address of the pharmacy where the prescription 
was filled [51]. It is thought that PDMPs can be 
helpful in reducing overdose deaths by allowing 
prescribers and pharmacists to identify patients 
who may be at risk for overdose such as those 
who appear to be engaging in doctor or pharmacy 
shopping, who may be taking excessively large 
doses of opioids, or who may have been prescribed 
opioids and benzodiazepines. In instances where a 
risk is noted, a physician or pharmacist can then do 
further assessment to determine if the individual 
may need a referral to substance abuse treatment 
or a change to her or his medication regimen. 
From a regulatory perspective, PDMPs can be 
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used to monitor prescribing activity and alert law 
enforcement or professional oversight committees 
to physicians whose prescribing behaviors appear 
to consistently run counter to accepted guidelines 
or may indicate the operation of a “pill mill”. At this 
time, the impact PDMPs have on reducing overdose 
deaths is unclear [52-55].
Medication Assisted Treatment 
For individuals who have an opioid use disorder, 
medication assisted treatment (MAT) can be 
helpful in reducing the risk for fatal overdose [56]. 
Medication assisted treatment (MAT) uses FDA-
approved medications to help individuals with 
opioid use disorders stop using opioids. The three 
drugs used for MAT are methadone, buprenorphine 
(Suboxone®), and naltrexone (Vivitrol®). Depending 
on the medication used, MAT works by reducing 
withdrawal symptoms and/or the euphoric 
effects associated with opioids, subsequently 
decreasing the need or desire to take opioid drugs 
and lowering the risk for overdose. Expanding the 
availability of MAT has been shown to reduce the 
rate of fatal overdoses at the community level. 
Similarly, providing MAT to persons in correctional 
facilities and to newly released persons can lessen 
the likelihood of overdose among this high-risk 
population [57-59]. 
Naloxone Distribution 
For persons who are experiencing an overdose, 
administration of naloxone can reduce the 
likelihood that the overdose will be fatal. Naloxone 
(e.g., Narcan®) is an FDA-approved drug that 
can reverse the physiological effects of an opioid 
overdose by displacing opioids from the brain 
receptors to which they bind and restoring normal 
breathing. Naloxone has no abuse potential as 
it has neither euphoric nor analgesic properties 
[60]. Naloxone can be administered through 
intravenous or intramuscular injection or through 
an intranasal atomizer. Naloxone has been widely 
used in emergency departments for reversing 
opioid overdoses since 1971. With the increase of 
fatal opioid overdoses nationally, most states have 
developed programming to provide naloxone to 
first responders (e.g., EMTs, police) so that they 
can administer care more quickly. More recently, 
community organizations throughout the country 
have worked to make naloxone available to lay 
people and especially to people who use either 
prescription or illicit opioids and their family and 
friends, as these are the individuals most likely to 
be present in the event of overdose. Naloxone is 
typically distributed to these individuals through 
opioid overdose and naloxone distribution 
programs (OOND). Persons who receive naloxone 
through these programs are trained how to identify 
an overdose, how to properly administer naloxone, 
and what they should do post-administration. 
Evaluation of OOND programs indicates that they 
are effective in training individuals on when and 
how to properly use naloxone that people trained 
to use naloxone will use it, that in communities 
with widespread implementation, rates of overdose 
decrease, and that OONDs are cost-effective [58, 
61-67]. The CDC reports that as of the end of 2014, 
over 150,000 laypeople had received naloxone kits 
and training in how to use them, with over 26,000 
overdose reversals reported [68].
CONCLUSION
Neither Indiana’s nor the nation’s epidemic of 
death from opioid overdoses can be easily solved. 
Reduction in deaths can only be realized when 
policymakers, prescribers, pharmacists, mental 
health professionals, persons in recovery, and the 
public at large begin to work together to address 
the overall opioid epidemic through controlling 
access to both legal and illegal opioids; identifying 
and providing easily accessible, effective, and 
affordable treatment to persons who need it; and 
encouraging persons who have friends or loved 
ones who are using opioids to seek out naloxone 
and become familiar with how and when to use it. 
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